Compare Northrop Grumman Corporation (NOC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Repligen Corporation Common Stock — how do they compare? Northrop Grumman Corporation trades at $504 (market cap $70.42B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Northrop Grumman Corporation is far larger — about 6.2× Repligen Corporation Common Stock's market cap, and Northrop Grumman Corporation pays a 1.99% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 82 Days and Repligen Corporation Common Stock for 0 Days on average.
| NOC | RGEN | |
|---|---|---|
Market Cap | $70.42B | $11.31B |
Volume | 1,218,886 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $768.02 | $194.57 |
52-Week Low | $473.46 | $102.87 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $84.40B | $11.20B |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $481.38, down 0.75% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 13%. Revenue growth remains steady, reaching $41.95B in 2025, while maintaining healthy profitability with 10.48% net margins. Recent news highlights both competitive challenges from Boeing's $20B fighter contract win and positive developments including new defense awards and record backlog.
The investment case balances strong fundamentals against near-term headwinds. Analyst consensus remains bullish with a $595.69 price target (24% upside), though technical indicators suggest caution. Key opportunities include defense budget tailwinds and B-21/Sentinel programs, while risks involve contract competition and execution challenges in major defense programs.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
